Author
Listed:
- HaoRan Tang
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
- Leo Leung
(Gene and Oncogene Targeting Team, CRUK Cancer Therapeutics Unit, The Institute of Cancer Research)
- Grazia Saturno
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
- Amaya Viros
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
- Duncan Smith
(Biological Mass Spectrometry Unit, Cancer Research UK Manchester Institute, University of Manchester)
- Gianpiero Di Leva
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
- Eamonn Morrison
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
- Dan Niculescu-Duvaz
(Gene and Oncogene Targeting Team, CRUK Cancer Therapeutics Unit, The Institute of Cancer Research)
- Filipa Lopes
(Gene and Oncogene Targeting Team, CRUK Cancer Therapeutics Unit, The Institute of Cancer Research)
- Louise Johnson
(Gene and Oncogene Targeting Team, CRUK Cancer Therapeutics Unit, The Institute of Cancer Research)
- Nathalie Dhomen
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
- Caroline Springer
(Gene and Oncogene Targeting Team, CRUK Cancer Therapeutics Unit, The Institute of Cancer Research)
- Richard Marais
(Molecular Oncology Group, Cancer Research UK Manchester Institute, University of Manchester)
Abstract
Lysyl oxidase (LOX) remodels the tumour microenvironment by cross-linking the extracellular matrix. LOX overexpression is associated with poor cancer outcomes. Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumour progression. We show that LOX regulates EGFR by suppressing TGFβ1 signalling through the secreted protease HTRA1. This increases the expression of Matrilin2 (MATN2), an EGF-like domain-containing protein that traps EGFR at the cell surface to facilitate its activation by EGF. We describe a pharmacological inhibitor of LOX, CCT365623, which disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumour cells in vivo. Thus, we show that LOX regulates EGFR cell surface retention to drive tumour progression, and we validate the therapeutic potential of inhibiting this pathway with the small molecule inhibitor CCT365623.
Suggested Citation
HaoRan Tang & Leo Leung & Grazia Saturno & Amaya Viros & Duncan Smith & Gianpiero Di Leva & Eamonn Morrison & Dan Niculescu-Duvaz & Filipa Lopes & Louise Johnson & Nathalie Dhomen & Caroline Springer , 2017.
"Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface,"
Nature Communications, Nature, vol. 8(1), pages 1-14, April.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14909
DOI: 10.1038/ncomms14909
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14909. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.